YOKNEAM, Israel, Sept. 19 /PRNewswire/ -- Lumenis Ltd., the world's largest medical laser company, announced today that it supplied an UltraPulse SurgiTouch CO2 laser with Digital AcuBlade microsurgery system to the Landspitalinn University Hospital in Reykjavik, Iceland. Lumenis' state of the art laser system, was used by Dr. Paul Castellanos to perform Trans-oral Laser Microsurgery (TLM) for the treatment of airway stenosis with obstructing neurofibromatosis of the laryngopharynx on a 9-year-old girl and four other patients.
The story will air September 20th at 19:35 on RUV a prime-time news show called Frettaaukinn, which will feature the story of the 9-year-old girl who was too sick to travel and whose illness was too advanced to be treated by any other means. Iceland did not have a laser capable of performing the delicate procedure, so Lumenis flew in a system, accessories and set-up personnel.
"No other laser system can match the precision needed to perform this type of delicate procedure," stated Dr. Paul Castellanos, Associate Professor of Laryngology Bronchoesophagology at the University of Alabama at Birmingham (UAB ), and we are very grateful to Lumenis for their help in this life saving mission. I certainly could not perform such an operation without the UltraPulse coupled with the Digital AcuBlade."
Trans-oral Laser Microsurgery (TLM) is an effective treatment for many diseases that affect the larynx. It is especially effective in the treatment of laryngeal cancer to preserve both the affected organ and its functionality. The UltraPulse CO2 lasers' high power pulsed energy combined with the robotic automation of the Digital AcuBlade creates the most effective tool for performing laser-assisted microsurgery(1). For some patients, like the 9-year-old girl in Iceland, surgery with the AcuBlade is the only treatment option.
"The automated technology behind the Digital AcuBlade is what makes this type of procedure possible," said Lloyd Diamond, Sr. VP and General Manager of Lumenis' Surgical and Vision businesses, "The scanning technology eliminates hand-tremor and other external factors, which can negatively impact the outcome. Because of this new technology, procedures on delicate areas such as in the larynx can now be performed."
"Lumenis is dedicated to healing and helping people around the globe with the best and most advanced systems in the market. We will continue to ensure access to our life-saving technology around the world, and to partner with physicians, so that together we will make a difference," added Mr. Dov Ofer, CEO of Lumenis.
About RUV - Iceland National Broadcasting Service
The Icelandic National Broadcasting Service - is an independent public service broadcaster, formally owned by the Icelandic state. It started operation in 1930. RUV is financially independent, its principal sources of income being the licence fee and revenues from advertisements. RUV's income can only be allocated for broadcasting purposes. RUV operates one television channel and two radio channels that cover the whole of Iceland. In addition regional radio programmes are broadcast from Isafjorour (West-Iceland), Akureyri (North-Iceland), Egilsstaoir (East-Iceland) and Selfoss (South-Iceland). According to the Broadcasting Act the main obligation of RUV is to promote the Icelandic language, Icelandic history and Iceland's cultural heritage. The RUV should also honour basic democratic rules, human rights and the freedom of speech and opinion.
Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. Lumenis' name is derived from the Latin meaning "Light of Life", highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: www.lumenis.com
For further information contact: Michelle Maydan Director of Corporate Communications 1-866-569-0597 +972-4-959-9004 e-mail: email@example.com
Lumenis(R) and its logo are trademarks or registered trademarks of the Lumenis Group of Companies.
(1) Remacle, Eur Arch Otorhinolaryngol (2005) 262 : 113-119 - New computer-guided scanner for improving CO2 laser-assisted microincision
Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.
|SOURCE Lumenis Ltd.|
Copyright©2009 PR Newswire.
All rights reserved